Rigel Pharmaceuticals Unveils Inducement Grants Under NASDAQ Rule 5635(c)(4)

On April 4, 2025, Rigel Pharmaceuticals, Inc., a notable player in the biotechnology sector, announced the granting of inducement awards under NASDAQ Listing Rule 5635(c)(4). These awards are a strategic move to attract and retain top talent within the company. The grants include stock options and restricted stock units, aimed at employees who are pivotal to Rigel's ongoing success.

Details of the Inducement Grants

Specifically, Rigel has issued a total of 23,350 stock options and restricted stock units to seven non-executive employees. These grants are designed with a vesting schedule over a four-year period, integrating a one-year cliff before any stock options can be exercised. This structure ensures that employees remain committed and incentivized to contribute positively to the company’s growth and innovation.

The awards are part of Rigel’s comprehensive inducement plan, which was thoughtfully approved by the Compensation Committee of the company's Board of Directors. By aligning the interests of employees with shareholder value, Rigel is enhancing its workforce's motivation while complying with regulatory expectations.

About Rigel Pharmaceuticals

Founded in 1996 and based in South San Francisco, California, Rigel Pharmaceuticals, Inc. focuses on the discovery and development of innovative therapies for patients suffering from hematologic disorders and cancer. The company is committed to addressing significant unmet medical needs through its robust pipeline of novel products.

Rigel’s approach combines extensive research with cutting-edge biotechnology to develop treatments that not only aim to improve health outcomes but also enhance the quality of life for patients. Its efforts have led to the successful marketing of several product candidates that leverage the latest scientific advancements.

Investors and stakeholders interested in learning more about Rigel Pharmaceuticals and its evolving product portfolio can visit Rigel’s official website for detailed information, including current updates and future potentials.

Conclusion

As Rigel Pharmaceuticals continues to grow, its strategic inducement grants reflect the company's commitment to cultivating a skilled and motivated workforce. By aligning employee interests with the company's long-term objectives, Rigel is positioning itself for sustained success in the biotechnology industry, ensuring that both employees and shareholders can benefit from the company's innovations.